(NASDAQ: TLSI) Trisalus Life Sciences's forecast annual revenue growth rate of 31.92% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Trisalus Life Sciences's revenue in 2025 is $40,207,000.On average, 9 Wall Street analysts forecast TLSI's revenue for 2025 to be $2,280,121,332, with the lowest TLSI revenue forecast at $2,154,461,090, and the highest TLSI revenue forecast at $2,376,552,453. On average, 9 Wall Street analysts forecast TLSI's revenue for 2026 to be $3,329,871,507, with the lowest TLSI revenue forecast at $3,016,245,526, and the highest TLSI revenue forecast at $3,752,119,899.
In 2027, TLSI is forecast to generate $4,682,405,405 in revenue, with the lowest revenue forecast at $4,421,541,738 and the highest revenue forecast at $4,927,030,672.